Q linea (QLINEA.ST) Osake Kurssi

Q linea AB, listed on the Stockholm Stock Exchange under the ticker QLINEA.ST, is a health care company headquartered in Uppsala, Sweden. The company, which went public on December 7, 2018, employs 122 full-time staff. Q linea AB operates as a holding company focused on the development and manufacturing of in-vitro diagnostic (IVD) solutions for infectious diseases. Its primary product candidate, ASTar, is a fully automated instrument designed for Antibiotic Susceptibility Testing (AST). The system utilizes proprietary disposables to measure bacterial antimicrobial susceptibility, providing a susceptibility profile within three to six hours directly from a positive blood culture. This rapid testing capability allows for early targeted antibiotic administration, specifically addressing the pathogen causing the infection. The company's main application targets sepsis identification in hospital patients, with its products primarily intended for use in hospital laboratories. Q linea AB's technology aims to improve diagnostic speed and precision in clinical settings, particularly for critical conditions requiring prompt treatment. The company's website is www.qlinea.com, where further information about its products and services can be found. As a publicly traded entity, Q linea AB is subject to standard financial reporting requirements for listed companies in Sweden. The company's focus on infectious disease diagnostics positions it within a specialized segment of the health care industry.